03b17fd7e1c07cb2…

{
  "id": "NCT00100334",
  "type": "Study",
  "data": {
    "briefSummary": "This is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-moderate Alzheimer's disease (AD). The primary objective of the study is to assess the safety of multiple IV injections of PPI-1019 in subjects with mild-moderate Alzheimer's disease.",
    "completionDate": "2005-08",
    "conditions": [
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 24,
    "enrollmentType": null,
    "nctId": "NCT00100334",
    "phase": "PHASE1, PHASE2",
    "sponsorId": "praecis-pharmaceuticals-inc",
    "startDate": "2004-12",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00100334"
  }
}